158 related articles for article (PubMed ID: 14741154)
1. Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines.
Arigita C; Jiskoot W; Westdijk J; van Ingen C; Hennink WE; Crommelin DJ; Kersten GF
Vaccine; 2004 Jan; 22(5-6):629-42. PubMed ID: 14741154
[TBL] [Abstract][Full Text] [Related]
2. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes.
Arigita C; Kersten GF; Hazendonk T; Hennink WE; Crommelin DJ; Jiskoot W
Vaccine; 2003 Feb; 21(9-10):950-60. PubMed ID: 12547608
[TBL] [Abstract][Full Text] [Related]
3. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.
Luijkx TA; van Dijken H; Hamstra HJ; Kuipers B; van der Ley P; van Alphen L; van den Dobbelsteen G
Infect Immun; 2003 Nov; 71(11):6367-71. PubMed ID: 14573657
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
5. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and immune responses to meningococcal recombinant porin complexes incorporated into liposomes.
Sánchez S; Abel A; Marzoa J; Gorringe A; Criado T; Ferreirós CM
Vaccine; 2009 Aug; 27(39):5338-43. PubMed ID: 19607954
[TBL] [Abstract][Full Text] [Related]
7. PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.
Vermont CL; Van Dijken HH; De Groot R; Van Alphen L; Van Den Dobbelsteen GP
Vaccine; 2004 Aug; 22(23-24):3008-13. PubMed ID: 15297049
[TBL] [Abstract][Full Text] [Related]
8. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
[TBL] [Abstract][Full Text] [Related]
9. Study of the stability of proteoliposomes as vehicles for vaccines against Neisseria meningitidis based on recombinant porin complexes.
Freixeiro P; Diéguez-Casal E; Costoya L; Seijo B; Ferreirós CM; Criado MT; Sánchez S
Int J Pharm; 2013 Feb; 443(1-2):1-8. PubMed ID: 23305865
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
Finney M; Vaughan T; Taylor S; Hudson MJ; Pratt C; Wheeler JX; Vipond C; Feavers I; Jones C; Findlow J; Borrow R; Gorringe A
Hum Vaccin; 2008; 4(1):23-30. PubMed ID: 17921703
[TBL] [Abstract][Full Text] [Related]
11. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
[TBL] [Abstract][Full Text] [Related]
12. Monitoring stability of meningococcal group C conjugate vaccines; correlation of physico-chemical methods and immunogenicity assays.
Ho MM; Lemercinier X; Bolgiano B; Corbel MJ
Dev Biol (Basel); 2000; 103():139-50. PubMed ID: 11214232
[TBL] [Abstract][Full Text] [Related]
13. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.
Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M
Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485
[TBL] [Abstract][Full Text] [Related]
14. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
15. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.
Luijkx T; van Dijken H; van Els C; van den Dobbelsteen G
Vaccine; 2006 Mar; 24(10):1569-77. PubMed ID: 16298029
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
[TBL] [Abstract][Full Text] [Related]
17. IgG antibody subclass responses determined by immunoblot in infants' sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine.
Martin S; Sadler F; Borrow R; Dawson M; Fox A; Cartwright K
Vaccine; 2001 Aug; 19(31):4404-8. PubMed ID: 11483265
[TBL] [Abstract][Full Text] [Related]
18. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.
Lehmann AK; Halstensen A; Aaberge IS; Holst J; Michaelsen TE; Sornes S; Wetzler LM; Guttormsen H
Infect Immun; 1999 May; 67(5):2552-60. PubMed ID: 10225920
[TBL] [Abstract][Full Text] [Related]
19. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
[TBL] [Abstract][Full Text] [Related]
20. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis.
Humphries HE; Williams JN; Blackstone R; Jolley KA; Yuen HM; Christodoulides M; Heckels JE
Vaccine; 2006 Jan; 24(1):36-44. PubMed ID: 16105711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
